You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKesson
Mallinckrodt
Express Scripts
Boehringer Ingelheim

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DAKLINZA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Daklinza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02565862 A Drug-drug Interaction Study Between Daclatasvir and Metformin Completed Radboud University Phase 1 2016-01-01 This study aims to provide clinical information on a potential drug-drug interaction between daclatasvir and metformin.
NCT02565888 A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat Completed Radboud University Phase 1 2015-11-01 This study aims to provide the evidence that 150mg of cobicistat will have the same effect on the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with atazanavir 300mg.
NCT02640157 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection Active, not recruiting AbbVie Phase 3 2015-12-01 The purpose of this study is to compare the safety and efficacy of ABT-493/ABT-530 to the combination of Sofosbuvir (SOF) and Daclatasvir (DCV) in adults with genotype 3 chronic hepatitis C virus (HCV) infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Daklinza

Condition Name

Condition Name for Daklinza
Intervention Trials
Hepatitis C 3
Healthy 3
Hepatitis C, Chronic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Daklinza
Intervention Trials
Hepatitis C 8
Hepatitis 7
Hepatitis C, Chronic 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Daklinza

Trials by Country

Trials by Country for Daklinza
Location Trials
United States 15
Egypt 3
Russian Federation 2
Netherlands 2
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Daklinza
Location Trials
Washington 1
Texas 1
Tennessee 1
Rhode Island 1
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Daklinza

Clinical Trial Phase

Clinical Trial Phase for Daklinza
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Daklinza
Clinical Trial Phase Trials
Completed 8
Active, not recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Daklinza

Sponsor Name

Sponsor Name for Daklinza
Sponsor Trials
Genuine Research Center, Egypt 3
Radboud University 2
R-Pharm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Daklinza
Sponsor Trials
Industry 9
Other 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Express Scripts
Moodys
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.